(Securities Code: 2796)
August 10, 2026
(Date of commencement of electronic provision measures: July 28, 2026)

To Our Shareholders

Masayuki Akiyama, President
Pharmarise Holdings Corporation
1-38-1 Chuo, Nakano-ku, Tokyo

Notice of Convocation of the 40th Ordinary General Meeting of Shareholders

We would like to take this opportunity to express our gratitude for your continued support of our operations.
Pharmarise Holdings Corporation (hereinafter "the Company") will hold the 40th Ordinary General Meeting of Shareholders as described below.
In convening this shareholders' meeting, the Company has taken measures for electronic provision of information and posted matters to be provided electronically as "Notice of Convocation of the 40th Ordinary General Meeting of Shareholders" on the following website on the Internet.
The Company's website: https://www.pharmarise.com/en/ir/share_holder.html
In addition to the above, the information is also posted on the following website on the Internet.
TSE website: https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show
We respectfully request that you exercise your voting rights, either by submitting your voting rights exercise form or via the Internet. When exercising your voting rights in writing or via the Internet, please exercise your voting rights by 6:00 p.m. (JST) on Thursday, August 27, 2026.

Details

1. Date and Time: Friday, August 28, 2026, at 10:00 a.m. (JST) (Doors will open at 9:30 a.m.)
2. Venue: Belle Salle Shinjuku Grand Conference Center, 5F, Sumitomo Fudosan Shinjuku Grand Tower, 8-17-1 Nishishinjuku, Shinjuku-ku, Tokyo
3. Meeting Agenda

Reports
1. Business reports and consolidated financial statements for the Company's 40th business term (from June 1, 2025 to May 31, 2026) and audit result reports of consolidated financial statements by the accounting auditor and the Audit & Supervisory Board.
2. Non-consolidated financial statements for the 40th business term (from June 1, 2025 to May 31, 2026)

Proposals
Proposal 1: Appropriation of Surplus
Proposal 2: Election of Nine (9) Directors
Proposal 3: Election of One (1) Audit & Supervisory Board Member

- When attending the meeting, please submit the enclosed voting rights exercise form at the reception desk to register your attendance.
- If there are any changes to the matters concerning the measures for the electronic provision, we will post the corrections on each website.

Reference Documents for the Ordinary General Meeting of Shareholders

Proposals and Reference Issues

Proposal 1: Appropriation of Surplus

Regarding the appropriation of surplus, the Company defines returns of profit to shareholders as one of the key management issues and has a basic policy of making stable and constant distribution of results commensurate with business growth.

In accordance with this policy, the Company proposes that the appropriation of surplus for the 40th business term be made as follows:

Year-end dividends

(1) Type of dividend property

Cash

(2) Allotment of dividend property and their aggregate amount

14 yen per common share of the Company, or 161,035,350 yen in total

(3) Effective date of dividends of surplus

August 31, 2026

Proposal 2: Election of Nine (9) Directors

The terms of office of nine (9) Directors will expire at the conclusion of this Ordinary General Meeting of Shareholders. We thus ask the shareholders to appoint nine (9) Directors.

The candidates for Directors are as follows:

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, position and responsibility in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of the Company held</th></tr>
<tr><td rowspan="17">1</td><td rowspan="16">Toshimichi Ohno
(April 16, 1950)

Reappointment</td><td>November 1971</td><td>Joined Marutake Co., Ltd.</td><td rowspan="16">426,690 shares</td></tr>
<tr><td>June 1984</td><td>Became President and Representative Director on founding the Company</td></tr>
<tr><td>January 1997</td><td>Became President and Representative Director of Minami Pharmacy Ltd.</td></tr>
<tr><td>May 2002</td><td>Became Director of Minami Pharmacy Co., Ltd.</td></tr>
<tr><td>September 2007</td><td>Became President and Representative Director of Fujii Pharmacy Co., Ltd.</td></tr>
<tr><td>June 2009</td><td>Became President and Representative Director of Pharmarise Co., Ltd. on the change of its business name to Pharmarise Holdings Corporation, and its incorporation in an incorporation-type company split</td></tr>
<tr><td>March 2013</td><td>Became President and Representative Director of Pharmarise Plus Co., Ltd.</td></tr>
<tr><td>August 2015</td><td>Became President, Representative Director and Executive Officer of the Company</td></tr>
<tr><td>October 2015</td><td>Became President and Representative Director of Pharmarise & Higuchi Corporation</td></tr>
<tr><td>August 2016</td><td>Became Chairperson and Representative Director of the Company</td></tr>
<tr><td>June 2017</td><td>Became Director of Mythos Co., Ltd.</td></tr>
<tr><td>January 2019</td><td>Became Chairperson of Pharmarise Co., Ltd.</td></tr>
<tr><td>March 2020</td><td>Became Director of Healthywork Corporation</td></tr>
<tr><td>December 2022</td><td>Became Director of Hokkaido Pharmarise Corporation</td></tr>
<tr><td>January 2024</td><td>Became Director of GOOD AID Co., Ltd.</td></tr>
<tr><td>August 2024</td><td>Became Chairperson and Director of the Company (to present)</td></tr>
<tr><td colspan="4">(Reasons for nomination)
Since its establishment, Mr. Toshimichi Ohno had served as President and Representative Director of the Company and has been highly evaluated inside and outside the Company for his superior management skills. The Company asks shareholders to re-appoint him as Director because he remains likely to contribute to the enhancement of its management.</td></tr>
</table>

No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company		Number of shares of the Company held
2	Sayoko Ohno (June 3, 1949) Reappointment	April 1973	Joined Marutake Co., Ltd.	513,170 shares
		July 1989	Became Director of the Company	
		July 2001	Became Managing Director of the Company	
		June 2009	Became Director of Pharmarise Co., Ltd. on the change of its business name to Pharmarise Holdings Corporation, and its incorporation in an incorporation-type company split (to present)	
		August 2009	Became Director of Minami Pharmacy Co., Ltd.	
		August 2019	Became Director of Laycare Center Co., Ltd. (to present)	
		August 2020	Became Vice Chairperson and Director of the Company (to present)	

(Reasons for nomination)

Ms. Sayoko Ohno is a person who has been committed to administrative operation, since she became Director in 1989 and Vice Chairperson and Director in 2020.

In response to the increasing momentum in the advancement of women in recent years and for the purpose of strengthening the administrative operation and employee education, the Company asks shareholders to re-appoint her as Director, considering her extensive experience.

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, position and responsibility in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of the Company held</th></tr>
<tr><td rowspan="2">3</td><td>Masayuki Akiyama
(February 16, 1967)

Reappointment</td><td>April 1995
July 1995
February 1997
June 2009

September 2009

August 2010
March 2014

August 2016
August 2018

October 2018
January 2019
March 2020

August 2021
January 2024</td><td>Joined Kyowa Shizuoka Co., Ltd.
Became Representative Director of Kyowa Shizuoka Co., Ltd.
Became Director of the Company as a result of merger
Became Senior Managing Director of Pharmarise Co., Ltd. on the change of its business name to Pharmarise Holdings Corporation, and its incorporation in an incorporation-type company split (to present)
Became Representative Director and President of Pharmarise Co., Ltd.
Became Senior Managing Director of the Company
Became Representative Director of Kinugawa Chouzai Center Co., Ltd.
Became Representative Director of Pharmarise Plus Co., Ltd.
Became President, Representative Director of the Company (to present)
Became Director of Chemist Co., Ltd. (to present)
Became Director of Pharmarise Co., Ltd. (to present)
Became Director of Kotobuki Data Bank Co., Ltd. (to present)
Became Director of Healthywork Corporation
Became Director of Mythos Co., Ltd.
Became President and Representative Director of GOOD AID Co., Ltd. (to present)</td><td>56,320 shares</td></tr>
<tr><td colspan="4">(Reasons for nomination)
Mr. Masayuki Akiyama is well versed in the overall business operations of the Company. He is now leading its business as President and Representative Director and has a strong track record, having served as a management team member for many years. The Company asks shareholders to re-appoint him as Director because he is expected to effectively enhance the Group’s decision-making and oversight functions, in addition to the above.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, position and responsibility in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of the Company held</th></tr>
<tr><td rowspan="2">4</td><td>Naonori Teramoto
(November 11, 1975)

New appointment</td><td>December 2000 Joined the Company
September 2011 Became General Manager of Store Operation Department, Business Division of Pharmarise Co., Ltd.
September 2017 Became President and Representative Director of Inose Shoji Y.K.
October 2018 Became Director of Chemist Co., Ltd. (to present)
September 2019 Became General Manager of Business Management Department of Pharmarise Co., Ltd.
April 2020 Became President and Representative Director of SUNMEDICAL Co., Ltd.
June 2022 Became President and Representative Director of Eiso Pharmacy LLC
August 2022 Became Director of Pharmarise Co., Ltd. (to present)
September 2023 Became President and Representative Director of Sankyo Iryo Yakuhin K.K.
September 2024 Became General Manager of Corporate Planning Department of the Company (to present)</td><td>2,200 shares</td></tr>
<tr><td colspan="3">(Reasons for nomination)
Mr. Naonori Teramoto has extensive experience in frontline operations and overseeing the dispensing pharmacy business for many years. He has been responsible for corporate management and business strategies as a representative of Group companies. Having served as the General Manager of the Corporate Planning Department and as a Director at key subsidiaries, he possesses a comprehensive understanding of all aspects of management. The Company believes that his strong practical insights and management skills will contribute to its sustainable growth and enhancement of corporate value in the medium to long term. The Company therefore asks shareholders to elect him as a Director.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, position and responsibility in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of
the Company held</th></tr>
<tr><td rowspan="9">5</td><td rowspan="8">Yoshihiro Tanaka
(October 9, 1976)

New appointment</td><td>May 2000</td><td>Joined the Company</td><td rowspan="8">4,500 shares</td></tr>
<tr><td>August 2012</td><td>Became President and Representative Director of the Minamiuonuma-gun Chouzai Center Co., Ltd.</td></tr>
<tr><td>June 2013</td><td>Became President and Representative Director of Tokyo Minami Pharmacy Co., Ltd.</td></tr>
<tr><td>September 2016</td><td>Became President and Representative Director of Pharmarise Co., Ltd.</td></tr>
<tr><td>June 2024</td><td>Became Director of GOOD AID Co., Ltd. (to present)</td></tr>
<tr><td>September 2024</td><td>Became Senior Managing Director of Pharmarise Co., Ltd. (to present)</td></tr>
<tr><td>December 2024</td><td>Became Director of Next PH CO. LTD. (to present)</td></tr>
<tr><td>February 2026</td><td>Became Senior Managing Director of Sankou Medical Co., Ltd. (to present)</td></tr>
<tr><td colspan="4">(Reasons for nomination)
Mr. Yoshihiro Tanaka has long and extensive experience in the dispensing pharmacy business, particularly in on-sight oversight and Group management. He has held roles such as President and Representative Director and General Manager of the dispensing business at key subsidiaries. He is currently demonstrating strong leadership as Senior Managing Director of key subsidiaries. The Company believes that his high level of expertise and management skills will contribute to its sustainable growth and enhancement of corporate value in the medium to long term. The Company therefore asks shareholders to elect him as a Director.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, position and responsibility in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of
the Company held</th></tr>
<tr><td rowspan="2">6</td><td>Mari Tsujimoto
(November 13, 1974)

New appointment</td><td>April 1998 Joined Hotel Okura Tokyo Co., Ltd.
October 2020 Joined the Company and became General Manager of the Personnel Training Section of the Human Resources Department
April 2022 Became Assistant Manager of Human Resources Department of the Company
March 2025 Became General Manager of the Administration Department of the Company (to present)</td><td>—</td></tr>
<tr><td colspan="3">(Reasons for nomination)
After gaining practical experience in sales planning and human resources in another industry, Ms. Tsujimoto has held key positions in human resource development, establishing a solid track record. She is currently leading efforts to strengthen the organization’s foundation, particularly focusing on ensuring thorough legal compliance, as the General Manager of the Administration Department. The Company believes that her extensive experience in human resources and management will contribute to achieving its healthy and sustainable growth, as well as enhancing corporate value in the medium to long term. The Company therefore asks shareholders to elect her as a Director.</td></tr>
</table>

No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company		Number of shares of the Company held
7	Ai Aizawa (April 15, 1967) Reappointment Outside Independent Officer	April 1996	Registered as an attorney (Daini Tokyo Bar Association) Joined Hamada Law Office	—
		September 2005	Became Chairperson of specified non-profit organization Mirai Kodomo Land	
		December 2007	Established Aizawa Law Office Became Director at the law office (to present)	
		June 2011	Became a member of Nerima Ward Administrative Evaluation Committee	
		April 2012	Became a member of the Fairness Committee of Nishi-Tokyo City, Ryusenen Association, and Tama Rokuto Science Museum Association	
		May 2012	Became Cabinet Office Reemployment Surveillance Inspector (part-time)	
		April 2013	Became a member of the Nishi-Tokyo City Community-Based Services Management Committee	
		April 2014	Became a Chofu-City ombudsman	
		April 2015	Became a member of the Nerima Ward Administrative Reform Promotion Council	
		June 2019	Became Director of social welfare corporation Oizumi Kikumi-kai (to present)	
		May 2020	Became a councilor of the Housing Finance Promotion Association (to present)	
		October 2022	Became a member of the Kokubunji City Political Ethics Review Board (to present)	
		January 2024	Became Director of the Company (to present)	
		July 2025	Became an employee tax accountant at Tax accountants' corporation kitajima accounting & consulting office (to present)	
	(Reasons for nomination and expected roles) Ms. Ai Aizawa has extensive experience as a lawyer and specialized knowledge regarding legal matters in general. The Company believes that she will continue to contribute to the effective enhancement of the decision-making and supervisory functions of its Board of Directors from the perspective of promoting sustained growth of the Company and improving its corporate value over the medium to long term. Accordingly, it asks shareholders to re-appoint her as Outside Director.			

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, position and responsibility in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of the Company held</th></tr>
<tr><td rowspan="2">8</td><td>Tsuneo Sonobe
(April 10, 1963)

Reappointment
Outside
Independent Officer</td><td>March 1995 Joined Takazono Corporation
March 1996 Became Director of Takazono Corporation
December 1999 Became Senior Managing Director of Takazono Corporation
November 2003 Became President and Representative Director of Takazono Corporation
June 2010 Became President and Representative Director of Takazono Technology Co., Ltd.
July 2012 Became Chairperson of TAKAZONO VIETNAM
February 2015 Became Director of Takazono Technology Co., Ltd. (to present)
April 2015 Became Chairperson and Representative Director of Takazono Corporation (to present)
May 2017 Became Director of the Japan Medical Industry Association (to present)
August 2020 Became Audit & Supervisory Board Member of the Company
August 2024 Became Director of the Company (to present)</td><td>—</td></tr>
<tr><td colspan="3">(Reasons for nomination and expected roles)
Mr. Tsuneo Sonobe has served for many years as President and Representative Director of Takazono Corporation, which plans, develops, manufactures and sells medical equipment and systems, and is currently engaged in the management of that company as Chairperson and Representative Director. The Company believes that he will contribute to the effective enhancement of the decision-making and oversight functions of the Board of Directors of the Company, utilizing his broad insight and extensive managerial experience. Accordingly, it asks shareholders to re-appoint him as Outside Director.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, position and responsibility in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of
the Company held</th></tr>
<tr><td rowspan="2">9</td><td>Naoko Ideguchi
(August 9, 1963)

New appointment
Outside
Independent Officer</td><td>April 1987
March 1994
April 2003

April 2004

April 2006
April 2006

April 2007

January 2013

April 2013

April 2013

April 2017

April 2018

June 2018

July 2023

April 2024</td><td>Joined Bohsei Pharmacy Co. Ltd.
Established Shin Iryo Kyoiku Kikaku and became its Representative
Became Director of Japanese Society of Community Pharmacy (JSCP) (to present)
Became Representative Director of Shin Iryo Sogo Kenkyusho K.K. (also known as New MEC Inc., the former Shin Iryo Kyoiku Kikaku)
Became Director and Advisor of Shin Iryo Sogo Kenkyusho
Became a full-time Lecturer in the School of Pharmacy at Nihon University
Became a councilor of the Japanese Society for Pharmaceutical Palliative Care and Sciences (to present)
Became Director of the Japanese Association of Home Care Pharmacies (to present)
Became a professor at the Graduate School of Pharmaceutical Sciences at Teikyo Heisei University (to present)
Became a professor at the Faculty of Pharmaceutical Sciences at the Teikyo Heisei University (to present)
Became a member of the Pharmaceutical Near-Miss Event Comprehensive Evaluation Panel of the Japan Council for Quality Health Care (JQ) (to present)
Became a delegate to the Japan Society of Clinical Safety (to present)
Became Vice Chairperson of the Japan Home Care Supporting Pharmacist Liaison Meeting (to present)
Became Chairperson of the Pharmacy Committee of the Tokyo Pharmaceutical Association (to present)
Became Vice Chairperson of the Japanese Society of Community Pharmacy (to present)</td><td>—</td></tr>
<tr><td colspan="4">(Reasons for nomination and expected roles)
Ms. Naoko Ideguchi is a university professor who holds two doctoral degrees, one in pharmacy and the other in education. She possesses advanced expertise in both fields and knowledge on human resource development. Additionally, she has extensive experience in the dispensing pharmacy business and in risk management, particularly related to medical safety. The Company believes that her extensive, advanced knowledge and her experience in corporate management will enhance the Board of Directors' effectiveness in decision-making and supervisory functions. The Company thus asks shareholders to elect her as an Outside Director.</td></tr>
</table>

(Notes)
1. The company names in the career summary are those at the time the Directors worked there.
2. There are no special interests between the Company and candidates for Directors.
3. Ms. Ai Aizawa, Mr. Tsuneo Sonobe and Ms. Naoko Ideguchi are Outside Director candidates.
4. Ms. Ai Aizawa, Director candidate, has served as Outside Director for two years and seven months.
5. Mr. Tsuneo Sonobe, Director candidate, has served as Outside Director for two years.
6. The Company registered Ms. Ai Aizawa and Mr. Tsuneo Sonobe, Outside Director candidates, as independent officers with Tokyo Stock Exchange. If they are elected, it will submit a notice to that effect to Tokyo Stock Exchange.
7. If Ms. Naoko Ideguchi, the candidate for Director, is appointed as Director, the Company plans to register her as an independent officer with the Tokyo Stock Exchange.
8. The Company has concluded an officers' liability insurance contract with an insurance company pursuant to Paragraph 1, Article 430-3 of the Companies Act. An outline of the insurance contract is as described on page 17 of the business report. If the candidates are elected, they will be included in the insured of the insurance contract. The Company plans to renew the said insurance contract under similar terms and conditions in September 2026.

Proposal 3: Election of One (1) Audit & Supervisory Board Member

The term of office of Audit & Supervisory Board Member Takayuki Enomoto will expire at the conclusion of this Ordinary General Meeting of Shareholders. We thus ask the shareholders to appoint one (1) Audit & Supervisory Board Member.
In addition, the consent of the Audit & Supervisory Board has been obtained for this proposal.
The candidate for Audit & Supervisory Board Member is as follows:

<table>
<tr><th>Name
(Date of birth)</th><th colspan="2">Career summary and position in the Company,
and significant concurrent positions outside the Company</th><th>Number of shares of the Company held</th></tr>
<tr><td rowspan="9">Takayuki Enomoto
(June 5, 1962)

Reappointment
Outside
Independent Officer</td><td>October 1987</td><td>Joined Chuo Audit Corporation</td><td rowspan="9">—</td></tr>
<tr><td>March 1991</td><td>Registered as a certified public accountant</td></tr>
<tr><td>January 1993</td><td>Established the Onogi Certified Public Accountant Office
Became Director at the accounting office (to present)</td></tr>
<tr><td>September 1995</td><td>Registered as a certified tax accountant</td></tr>
<tr><td>August 2017</td><td>Selected Substitute Audit & Supervisory Board Member of the Company</td></tr>
<tr><td>September 2017</td><td>Became Audit & Supervisory Board Member of the Company (to present)</td></tr>
<tr><td>July 2022</td><td>Became a standing secretary at the Japanese Institute of Certified Public Accountants, Tokyo Chapter
(to present)</td></tr>
<tr><td>July 2025</td><td>Became a standing auditor at the Tokyo Certified Public Tax Accountants' Association (to present)</td></tr>
<tr><td></td><td></td></tr>
<tr><td colspan="4">(Reasons for nomination)
Mr. Takayuki Enomoto established an accountant office in 1993 after working for an audit corporation. Mr. Takayuki Enomoto has extensive experience and high levels of expertise gained through many years' involvement in the business of corporate accounting and tax affairs. The Company proposes his reappointment as Outside Audit & Supervisory Board Member based on the judgment that he will fulfil his duties as Audit & Supervisory Board Member of the Company in an appropriate manner.</td></tr>
</table>

(Notes)
1. Candidate for Audit & Supervisory Board Member Mr. Takayuki Enomoto has no special relationships with the Company.
2. Mr. Takayuki Enomoto is a candidate for Outside Audit & Supervisory Board Member.
3. Mr. Takayuki Enomoto will have served as Outside Audit & Supervisory Board Member for eight years and eleven months.
4. Mr. Takayuki Enomoto is registered as an independent officer with Tokyo Stock Exchange, Inc., and if he is reelected, the Company will keep him registered as an independent officer.
5. The Company has concluded an officers' liability insurance contract with an insurance company pursuant to Paragraph 1, Article 430-3 of the Companies Act. An outline of the insurance contract is as described on page 17 of the business report. If the candidate is elected, he will be included in the insured of the insurance contract. The Company plans to renew the said insurance contract under similar terms and conditions in September 2026.

(Reference) Table showing the expertise, knowledge, experience, abilities and other skills of Directors and Audit & Supervisory Board Members (skills matrix)

The key expertise, knowledge, experience, abilities and other skills possessed by the Company's Directors and Audit & Supervisory Board Members are as follows.

Officer		Corporate management	Sales Store development
Name	Position		
Toshimichi Ohno	Director (Reappointment)	●	●
Sayoko Ohno	Director (Reappointment)	●	
Masayuki Akiyama	Director (Reappointment)	●	●
Naonori Teramoto	Director (New appointment)	●	
Yoshihiro Tanaka	Director (New appointment)	●	●
Mari Tsujimoto	Director (New appointment)		
Ai Aizawa	Outside Director (Reappointment)		
Tsuneo Sonobe	Outside Director (Reappointment)	●	
Naoko Ideguchi	Outside Director (New appointment)	●	
Makoto Miura	Corporate Auditor (In the term of office)	●	
Takayuki Enomoto	Outside Audit & Supervisory Board Member (Reappointment)	●	
Takao Suzuki	Outside Audit & Supervisory Board Member (In the term of office)		

(Note) The matrix above does not represent all of each officer's knowledge, experience, and expertise, but rather indicates specific areas of expectations of them.

Business strategy M&A	Financial accounting	Women's diversity and inclusion	Personnel and labor management HR development	Legal affairs Compliance Risk management	ESG Sustainability	Dispensing pharmacy business
●				●	●	●
		●	●	●	●	●
●				●	●	●
●	●			●	●	●
				●	●	●
		●	●	●	●	
		●	●	●		
				●		●
		●	●	●		●
	●					●
	●			●		
●	●			●		